OverviewSuggest Edit

AbbVie is a pharmaceutical company that discovers, develops, and markets oncology, virology, metabolics and hormones, endocrinology, and other products. Its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.
TypePublic
Founded2013
HQLake Bluff, US
Websiteabbvie.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Jan 2020)30,000
Job Openings961
Revenue (FY, 2019)$33.3 B(+2%)
Share Price (Sept 2020)$87.1 (-1%)
Cybersecurity ratingCMore

Key People/Management at AbbVie

Richard A. Gonzalez

Richard A. Gonzalez

Chairman of the Board and Chief Executive Officer
Michael E. Severino

Michael E. Severino

Vice Chairman and President
Laura J. Schumacher

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer
Carlos Alban

Carlos Alban

Vice Chairman, Chief Commercial Officer
Rae L. Livingston

Rae L. Livingston

Chief Equality Officer
Henry O. Gosebruch

Henry O. Gosebruch

Executive Vice President, Chief Strategy Officer
Show more

AbbVie Office Locations

AbbVie has offices in Lake Bluff, Cambridge, Mettawa, North Chicago and in 60 other locations
Lake Bluff, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Mettawa, US
26525 Riverwoods Blvd
North Chicago, US
1401 Sheridan Rd
Redwood City, US
1500 Seaport Blvd
South San Francisco, US
450 E Jamie Ct
Show all (67)

AbbVie Financials and Metrics

AbbVie Revenue

Embed Graph
View revenue for all periods
AbbVie's revenue was reported to be $33.27 b in FY, 2019 which is a 1.6% increase from the previous period.
USD

Revenue (Q2, 2020)

10.4b

Gross profit (Q2, 2020)

6.7b

Gross profit margin (Q2, 2020), %

64.4%

Net income (Q2, 2020)

(739.0m)

EBIT (Q2, 2020)

752.0m

Market capitalization (23-Sept-2020)

153.8b

Closing stock price (23-Sept-2020)

87.1

Cash (30-Jun-2020)

6.0b

EV

235.2b
AbbVie's current market capitalization is $153.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

25.6b28.2b32.8b33.3b

Revenue growth, %

12%10%16%2%

Cost of goods sold

5.8b7.0b7.7b7.4b

Gross profit

19.8b21.2b25.0b25.8b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

6.5b6.9b7.0b7.9b8.3b8.2b7.8b8.3b8.5b8.6b10.4b

Cost of goods sold

1.6b1.5b1.6b1.9b1.9b1.8b1.7b1.8b1.9b1.9b3.7b

Gross profit

4.9b5.4b5.4b6.0b6.3b6.4b6.1b6.4b6.6b6.7b6.7b

Gross profit Margin, %

75%78%77%76%77%78%78%78%77%77%64%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.1b9.3b7.3b39.9b

Accounts Receivable

4.8b5.1b5.4b5.4b

Prepaid Expenses

3.6b4.7b1.9b2.4b

Inventories

1.4b1.6b1.6b1.8b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

4.7b6.1b8.4b9.0b3.5b8.0b4.9b5.2b10.6b41.1b6.0b

Accounts Receivable

4.7b4.9b4.9b5.8b5.8b5.8b5.7b5.5b5.5b6.4b8.4b

Prepaid Expenses

3.2b3.3b2.7b3.4b2.7b2.1b1.8b2.3b2.1b2.4b2.8b

Inventories

1.4b1.6b1.8b1.7b1.6b1.8b1.7b1.9b1.9b1.8b4.1b
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

6.0b5.3b5.7b7.9b

Depreciation and Amortization

1.2b1.5b1.8b2.0b

Inventories

(38.0m)93.0m(226.0m)(231.0m)

Accounts Payable

(1.2b)425.0m190.0m(1.1b)
USDFY, 2016

Revenue/Employee

915.6k

Debt/Equity

7.9 x

Debt/Assets

0.6 x

Financial Leverage

14.3 x
Show all financial metrics

AbbVie Operating Metrics

AbbVie's Patients was reported to be 30 m in FY, 2018.
FY, 2018

Partners

220

Patients

30 m

Programs

292

Suppliers

51 k
Show all operating metrics

AbbVie Acquisitions / Subsidiaries

Company NameDateDeal Size
MavupharmaJuly 15, 2019
AllerganJune 25, 2019$80 b
Stem CentRxApril 28, 2016$5.80 b
Pharmacyclics IncMarch 04, 2015
ImmuVenJanuary 01, 2014
AbbVie AB
AbbVie AG
AbbVie AS
AbbVie A/S
AbbVie Australasia Holdings Limited
Show more

AbbVie Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

AbbVie Revenue Breakdown

Embed Graph

AbbVie revenue breakdown by geographic segment: 28.1% from International and 71.9% from United States

AbbVie Online and Social Media Presence

Embed Graph

AbbVie News and Updates

Global Facial Aesthetics Market (2020 to 2024) - Featuring AbbVie, Adoderm & Alma Lasers Among Others

Dublin, Sept. 23, 2020 (GLOBE NEWSWIRE) -- The "Global Facial Aesthetics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The facial aesthetics market is poised to grow by USD 2.57 bn during 2020-2024 progressing at a CAGR of 7% during the forecast period. The reports…

Global DNA Damage Response Drugs Market Analysis and Competitor Profiles 2020, Featuring AbbVie Inc., AstraZeneca plc, Bayer AG, Pfizer Inc. and More

DUBLIN, Sept. 15, 2020 /PRNewswire/ -- The "Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets....

Daily Dividend Report: AbbVie, Bristol Myers Squibb, Colgate-Palmolive, American Tower, Cerner

Daily Dividend Report: AbbVie, Bristol Myers Squibb, Colgate-Palmolive, American Tower, Cerner

Drugmaker AbbVie pressures reluctant employees to return to work, raising safety questions

Even if employees have demonstrated an ability to do their jobs from home, the company expects them to report to the office to foster creativity and innovation under its phased-in return-to-work plan.

I-Mab's stock soars after AbbVie collaboration, which could be worth nearly $2 billion

Shares of I-Mab soared 17% in premarket trading Friday toward a record high, after the China-based biotechnology company announced a collaboration agreement with AbbVie Inc. to develop and commercialize I-Mab's lemzoparlimab for the treatment of multiple cancers. AbbVie's stock edged up 0.1% ahead…

AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab

AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab
Show more

AbbVie Frequently Asked Questions

  • When was AbbVie founded?

    AbbVie was founded in 2013.

  • Who are AbbVie key executives?

    AbbVie's key executives are Richard A. Gonzalez, Michael E. Severino and Laura J. Schumacher.

  • How many employees does AbbVie have?

    AbbVie has 30,000 employees.

  • What is AbbVie revenue?

    Latest AbbVie annual revenue is $33.3 b.

  • What is AbbVie revenue per employee?

    Latest AbbVie revenue per employee is $1.1 m.

  • Who are AbbVie competitors?

    Competitors of AbbVie include Gilead Sciences, Immunomedics and Sanofi.

  • Where is AbbVie headquarters?

    AbbVie headquarters is located at 1 Waukegan Rd, Lake Bluff.

  • Where are AbbVie offices?

    AbbVie has offices in Lake Bluff, Cambridge, Mettawa, North Chicago and in 60 other locations.

  • How many offices does AbbVie have?

    AbbVie has 67 offices.